M. Pelat

发表

H11 Kinase Prevents Myocardial Infarction by Preemptive Preconditioning of the Heart

S. Vatner, L. Bertrand, A. Ginion, 2006, Circulation research.

Rosuvastatin Decreases Caveolin-1 and Improves Nitric Oxide–Dependent Heart Rate and Blood Pressure Variability in Apolipoprotein E−/− Mice In Vivo

J. Balligand, O. Feron, C. Dessy, 2003, Circulation.

Regulation of the mammalian heart function by nitric oxide.

J. Balligand, M. Pelat, C. Belge, 2005, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

Caveolin-1 Expression Is Critical for VEGF-Induced Ischemic Hindlimb Collateralization and Nitric Oxide – Mediated Angiogenesis

V. Grégoire, J. Balligand, O. Feron, 2004 .

Potential Therapeutic Value of Urotensin II Receptor Antagonist in Chronic Kidney Disease and Associated Comorbidities

F. Barbe, M. Pelat, J. Guillon, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Statins and Hypertension

J. Balligand, M. Pelat, Michel Pelat1, 2004, Seminars in vascular medicine.

Changes in vascular alpha1‐ and alpha2‐adrenoceptor responsiveness by selegiline treatment

M. Pelat, M. Berlan, J. Senard, 2001, Fundamental & clinical pharmacology.

Nitric oxide "at heart": emerging paradigms after a decade.

J. Balligand, M. Pelat, P. Massion, 2005, Archives des maladies du coeur et des vaisseaux.

Nitric Oxide and the Heart: Update on New Paradigms

J. Balligand, M. Pelat, C. Belge, 2005, Annals of the New York Academy of Sciences.

Cardiomyocyte-Restricted Overexpression of Endothelial Nitric Oxide Synthase (NOS3) Attenuates &bgr;-Adrenergic Stimulation and Reinforces Vagal Inhibition of Cardiac Contraction

J. Balligand, O. Feron, C. Dessy, 2004, Circulation.

Update on New Paradigms

J. Balligand, M. Pelat, C. Belge, 2005 .

Peripheral cardiovascular actions of SR 58611 A, a beta 3‐adrenoceptor agonist, in the dog: lack of central effect

J. Montastruc, M. Pelat, D. Langin, 1999, Fundamental & clinical pharmacology.

High Isoproterenol Doses Are Required to Activate β3-Adrenoceptor-Mediated Functions in Dogs

J. Montastruc, M. Pelat, J. Senard, 2003, Journal of Pharmacology and Experimental Therapeutics.

Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat.

O. Rascol, M. Pelat, C. Brefel‐Courbon, 1998, European journal of pharmacology.

Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) potentiates postsynaptic vagal inhibition of cardiac contraction in vivo and in vitro

J. Balligand, O. Feron, C. Dessy, 2004 .

Alpha2-adrenoceptor function in arterial hypertension associated with obesity in dogs fed a high-fat diet

J. Montastruc, M. Pelat, J. Senard, 2002, Journal of hypertension.

Weight Loss-Associated Induction of Peroxisome Proliferator-Activated Receptor-&agr; and Peroxisome Proliferator–Activated Receptor-&ggr; Correlate With Reduced Atherosclerosis and Improved Cardiovascular Function in Obese Insulin-Resistant Mice

M. Herregods, J. Balligand, J. Ganame, 2004, Circulation.

Characterization of the central muscarinic cholinoceptors involved in the cholinergic pressor response in anesthetized dogs.

O. Rascol, M. Pelat, C. Gharib, 1999, European journal of pharmacology.

Protein turnover in cardiac cell growth and survival.

C. Depré, Nadia Hedhli, M. Pelat, 2005, Cardiovascular research.

Impaired atrial M(2)-cholinoceptor function in obesity-related hypertension.

M. Pelat, J. Senard, M. Berlan, 1999, Hypertension.

Fluoxetine in orthostatic hypotension of Parkinson's disease: A clinical and experimental pilot study

O. Blin, O. Rascol, J. Montastruc, 1998, Fundamental & clinical pharmacology.

Caveolin-1 Expression Is Critical for Vascular Endothelial Growth Factor–Induced Ischemic Hindlimb Collateralization and Nitric Oxide–Mediated Angiogenesis

Jean-Luc Balligand, Vincent Grégoire, Chantal Dessy, 2004, Circulation research.

Cardiac Transcriptome Analysis in Obesity-Related Hypertension

P. Rouet, P. Philip-Couderc, M. Pelat, 2003, Hypertension.

SAR340835, a Novel Selective Na+/Ca2+ Exchanger Inhibitor, Improves Cardiac Function and Restores Sympathovagal Balance in Heart Failure

F. Barbe, M. Pelat, Thomas Lartigue, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Control of blood pressure variability in caveolin-1-deficient mice: role of nitric oxide identified in vivo through spectral analysis.

J. Balligand, C. Dessy, M. Pelat, 2008, Cardiovascular research.

Weight-loss changes PPAR expression, reduces atherosclerosis and improves cardiovascular function in obese insulin-resistant mice

M. Herregods, J. Balligand, J. Ganame, 2003 .

Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.

M. Herregods, J. Balligand, M. Pelat, 2008, European heart journal.

4P-1061 Altered blood pressure and heart rate variability in hypercholesterolemic apoE-/-mice is corrected by rosuvastatin independently of its plasma lipid lowering activity

J. Balligand, C. Dessy, M. Pelat, 2003 .

Differential Modulation of Caveolin-1 Expression in Cells of the Vasculature by Statins Pelat and coworkers1 demonstrated that rosuvastatin decreases caveolin-1 expression in the cardiovasculature of dyslipidemic mice. By decreasing the expression of caveolin-1, an inhibitor of endothelial NO syntha

C. Dessy, M. Pelat, P. Massion, 2004 .

M. Herregods, J. Balligand, J. Ganame, 2004, Circulation.